.svg)
.jpg)
In today’s fast-paced world, patients and healthcare providers require drug delivery systems such as sublingual tablets, which offer rapid therapeutic action and improved bioavailability. Sublingual technology has gained significant attention because it enables direct absorption of the active pharmaceutical ingredient through the sublingual mucosa into the systemic circulation. Sublingual tablets support this mechanism by bypassing hepatic first-pass metabolism, which improves bioavailability and accelerates the onset of action.
This route of administration proves particularly valuable for drugs that undergo extensive hepatic metabolism or show poor gastrointestinal absorption. Therapeutic categories such as cardiovascular drugs, analgesics, and antiemetics benefit significantly from sublingual delivery. Sublingual tablets also enhance patient compliance, especially among paediatric, geriatric, and uncooperative patients, because they allow convenient administration without the need for water or swallowing.
Sublingual tablets dissolve under the tongue and allow the drug to diffuse rapidly across the highly vascularised sublingual mucosa. This direct absorption pathway enables faster systemic drug availability compared with conventional oral tablets, which undergo gastrointestinal absorption and hepatic metabolism.
The effectiveness of a sublingual formulation depends on rapid disintegration, efficient dissolution, and optimal permeation through the mucosal membrane. These characteristics ensure that the drug releases quickly and absorbs efficiently within the limited residence time available in the oral cavity.
When a patient places a sublingual tablet under the tongue, saliva initiates rapid tablet disintegration and dissolution. The released drug permeates through the thin epithelial barrier of the sublingual mucosa and enters the bloodstream through the dense capillary network present in this region.
This mechanism enables faster therapeutic response and higher bioavailability. Proper formulation of sublingual tablets ensures sufficient retention of the drug at the absorption site and minimises swallowing, which could reduce therapeutic efficiency.
Manufacturers develop sublingual tablets using two primary approaches:
Both approaches support effective sublingual tablet formulation by balancing disintegration, stability, and manufacturability.
The selection of excipients plays a critical role in the formulation of sublingual tablets. Key excipients include:
These components support rapid disintegration, drug release, and efficient absorption.
Manufacturers prepare moulded sublingual tablets through a structured process:
Stability remains an essential consideration in sublingual tablet formulation. Manufacturers improve stability through:
Manufacturers commonly use the following techniques:
Both methods support consistent quality in sublingual formulation development.
Compressed sublingual tablets require carefully selected excipients:
Taste masking plays a critical role in improving patient acceptance and treatment adherence.
The particle size of the active pharmaceutical ingredient significantly influences dissolution rate and absorption. Smaller particle size increases surface area and enhances drug release. Manufacturers must carefully control particle size distribution to ensure consistent performance.
Tablet properties such as hardness, porosity, size, and wettability also affect disintegration behaviour. Highly porous tablets disintegrate rapidly but require optimisation to maintain sufficient mechanical strength during handling and packaging.
Bioadhesive polymers can improve retention at the absorption site and enhance drug absorption by prolonging mucosal contact.
Advanced sublingual technologies, such as bioadhesive delivery systems, enhance the performance of the drug delivery system. These approaches support rapid disintegration, efficient drug release, and improved bioavailability while maintaining structural integrity.
Microencapsulation and polymer-based technologies further improve stability, taste masking, and absorption efficiency in modern sublingual tablet formulations.
Evaluation ensures consistent quality, performance, and safety.
Manufacturers conduct quality control tests, including:
These tests ensure consistent dosage and mechanical stability.
Rapid disintegration remains a critical requirement for sublingual tablets. Specialised testing methods simulate oral cavity conditions using minimal fluid volumes to evaluate realistic performance.
Texture analyser-based testing provides precise measurement of disintegration behaviour under controlled conditions.
Wetting time directly influences drug release and absorption efficiency. Manufacturers evaluate friability to ensure adequate durability during transport and handling.
Optimisation ensures rapid disintegration without compromising mechanical integrity.
Measure key pharmacokinetic parameters such as Cmax (maximum concentration), Tmax (time to reach maximum concentration), and AUC (area under the curve) to evaluate the drug's bioavailability.
Conduct ex vivo studies using porcine oral mucosa to gain insights into drug permeation and absorption. Use techniques like diffusion cells and Franz diffusion cells for these studies.
Critical quality attributes determine the effectiveness of sublingual tablet formulation:
Rapid disintegration and dissolution remain essential because the sublingual environment offers limited fluid volume and short absorption time.
Taste masking techniques such as sweeteners, flavouring agents, solid dispersions, and encapsulation improve patient acceptance and compliance.
Sublingual drug delivery systems continue to evolve with new dosage forms such as films, sprays, and bioadhesive tablets. These systems enhance drug stability, absorption efficiency, and patient convenience.
Nitroglycerin sublingual tablets remain one of the most widely used examples, providing rapid relief in angina by enabling immediate systemic absorption.
Advances in polymer science, bioadhesion technologies, and particle engineering continue to improve the performance of sublingual formulations and therapeutic outcomes.
At ZIM Laboratories, this innovation extends beyond conventional tablet formats - the proprietary Mucostrip® technology is specifically engineered for sublingual and buccal drug delivery, while the Thinoral platform produces rapidly dissolving, non-sticky Oral Thin Films with higher drug loading capacity and faster release profiles, directly addressing bioavailability challenges in poorly soluble molecules by bypassing first-pass metabolism.
ZIM Laboratories Limited is a therapy-agnostic & innovative drug delivery solution provider focusing on enhancing patient convenience and treatment adherence to drug intake. We offer a range of technology-based drug delivery solutions and non-infringing proprietary manufacturing processes to develop, manufacture, and supply innovative and differentiated generic pharmaceutical products to our customers globally. At ZIM Labs, we provide our customers with a comprehensive range of oral solid value-added, differentiated generic products in semi-finished and finished formulations. These include granules, pellets (sustained, modified, and extended-release), taste-masked powders, suspensions, tablets, capsules, and Oral Thin Films (OTF).
